Selinexor in Combination with Venetoclax and Azacitidine for Newly Diagnosed (ND) Unfit Acute Myeloid Leukemia (AML): A Multicenter, Open-Label Prospective Study

被引：1
|
作者：
Yang, Li [1 ]
Chen, Fangli [1 ]
Liang, Hong [2 ]
Bai, Yunsong [3 ]
Wu, Wenzhong [4 ]
Yan, Xiaojing [5 ]
Ren, Jinhai [6 ]
Li, Si [2 ]
Yu, Yang [2 ]
Tong, Laigen [4 ]
Pan, Deng [5 ]
Liu, Ligen [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Tongren Hosp, Sch Med, Dept Hematol,Hongqiao Int Inst Med, Shanghai, Peoples R China
[2] Harbin Inst Hematol & Oncol, Dept Hematol & Oncol, Haerbin, Peoples R China
[3] Jilin Univ, China Japan Union Hosp, Dept Hematol, Changchun, Peoples R China
[4] Yixing Peoples Hosp, Yixing, Peoples R China
[5] China Med Univ, Hosp 1, Shenyang, Peoples R China
[6] Hebei Med Univ, Hosp 2, Dept Hematol, Shijiazhuang, Hebei, Peoples R China
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-184581
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] OMNIVERSE: A Phase 1b/2 Study of Oral Azacitidine Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed (ND) Acute Myeloid Leukemia (AML)
    Ravandi, Farhad
    Carraway, Hetty E.
    Taningco, Lilia
    Dilley, Kimberley
    Laille, Eric
    Gong, Jing
    de Menezes, Daniel Lopes
    Wei, Andrew H.
    BLOOD, 2021, 138
  • [32] Single-institution experience of venetoclax combined with azacitidine in newly diagnosed acute myeloid leukemia patients
    Yu, Hong
    Wang, Chaomeng
    Lei, Yingying
    Li, Lijuan
    Wang, Huaquan
    Wang, Guojin
    Xing, Limin
    Guan, Jing
    Song, Jia
    Wu, Yuhong
    Liu, Hong
    Qu, Wen
    Wang, Xiaoming
    Shao, Zonghong
    Fu, Rong
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 127
  • [33] A Systematic Review of Venetoclax and Azacitidine: Effectiveness and Safety for Newly Diagnosed and Relapsed Acute Myeloid Leukemia Patients
    Ibrahim, Ahmed
    Yousaf, Muhammad Abdullah
    Anwar, Zain
    Anum
    Batool, Maha
    Rehman, Mohammad
    Safdar, Omar A.
    Khattak, Zeeshan Ahmed
    Faraz, Fatima
    Khalid, Huma
    BLOOD, 2023, 142
  • [34] Real-World Efficacy and Hematologic Toxicity of Azacitidine and Venetoclax in a Cohort of Elderly Patients Unfit for Intensive Chemotherapy With Newly Diagnosed Acute Myeloid Leukemia
    Wysoglad, Hubert
    Krawczyk, Katarzyna
    Ochrem, Bogdan
    Madry, Krzysztof
    Drozd-Sokolowska, Joanna
    Sacha, Tomasz
    Basak, Grzegorz
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S294 - S294
  • [35] Cytopenia Management in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Azacitidine in the VIALE-A Study
    Pratz, Keith W.
    DiNardo, Courtney D.
    Selleslag, Dominik
    Li, Junmin
    Yamamoto, Kazuhito
    Konopleva, Marina
    McDonald, Andrew
    Babu, Sunil
    Stevens, Don A.
    Kantarjian, Hagop M.
    Traina, Fabiola
    Venditti, Adriano
    Mayer, Jiri
    Montez, Melissa
    Ramsingh, Giridharan
    Jin, Huan
    Ainsworth, William
    Duan, Yinghui
    Svensson, Anders Erik
    Werner, Michael
    Potluri, Jalaja
    Jonas, Brian A.
    BLOOD, 2020, 136
  • [36] Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia
    Jonas, Brian A.
    Wei, Andrew H.
    Recher, Christian
    DiNardo, Courtney D.
    Jang, Jun-Ho
    Pratz, Keith
    Panayiotidis, Panayiotis
    Montesinos, Pau
    Yeh, Su-Peng
    Ivanov, Vladimir
    Fiedler, Walter
    Yamauchi, Takahiro
    Duan, Yinghui
    Mendes, Wellington
    Potluri, Jalaja
    Tews, Bjorn
    Ofran, Yishai
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (08) : E299 - E303
  • [37] Azacitidine in combination with HAG for newly diagnosed and relapsed/refractory AML: a prospective cohort study
    Pan, Hong
    Gao, Zhen
    Lian, Yu
    Zhao, Jingyu
    Zhang, Lele
    Li, Weiwang
    Li, Ruonan
    Liang, Qian
    Xu, Jing
    Li, Liyun
    Yu, Xiao
    Kuang, Zhexiang
    Shi, Jun
    Fang, Liwei
    ANNALS OF HEMATOLOGY, 2025,
  • [38] VENETOCLAX IN COMBINATION WITH AZACITIDINE IS COST-EFFECTIVE VS. AZA FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: A CANADIAN PERSPECTIVE
    Guinan, K.
    Mathurin, K.
    Au, Y.
    Schuh, A. C.
    Bui, C. N.
    Chai, X.
    Lachaine, J.
    VALUE IN HEALTH, 2022, 25 (07) : S344 - S344
  • [39] Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy
    Wang, Eunice S.
    Montesinos, Pau
    Minden, Mark D.
    Lee, Je-Hwan
    Heuser, Michael
    Naoe, Tomoki
    Chou, Wen-Chien
    Laribi, Kamel
    Esteve, Jordi
    Altman, Jessica K.
    Havelange, Violaine
    Watson, Anne-Marie
    Patkowska, Elzbieta
    Liu, Shufang
    Wu, Ruishan
    Philipose, Nisha
    Hill, Jason E.
    Gill, Stanley
    Rich, Elizabeth Shima
    Tiu, Ramon V.
    BLOOD, 2021, 138
  • [40] Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML).
    Dinardo, Courtney Denton
    Stein, Anthony Selwyn
    Stein, Eytan M.
    Fathi, Amir Tahmasb
    Frankfurt, Olga
    Schuh, Andre C.
    Martinelli, Giovanni
    Patel, Prapti Arvind
    Raffoux, Emmanuel
    Tan, Peter
    Zeidan, Amer Methqal
    de Botton, Stephane
    Kantarjian, Hagop M.
    Stone, Richard M.
    Lam, Du Hung
    Gong, Jing
    Zhang, Vickie
    Winkler, Thomas
    Wu, Bin
    Vyas, Paresh
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345